Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Early, intensive statin treatment reduces ‘hard’ cardiovascular outcomes after acute coronary syndrome

Schwartz, Gregory G, Fayyad, Rana, Szarek, Michael, DeMicco, David, Olsson, Anders G · 2017 · European Journal of Preventive Cardiology

Abstract

Background Early, intensive statin treatment is the standard of care after acute coronary syndrome (ACS). However, the benefit of this approach to prevent major adverse cardiovascular events has been demonstrated in only one randomised, placebo controlled trial. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial demonstrated that atorvastatin 80 mg daily, compared with placebo, reduced time to first occurrence of death, non-fatal myocardial infarction, resuscitated cardiac arrest, or hospitalisation for unstable angina (stroke not included) during the 16 week period following ACS. However, there were no significant effects on individual components of the composite endpoint except unstable angina. This led some to question whether early, intensive statin treatment reduces 'hard' events after ACS. Aim The burden of coronary heart disease after ACS, and therefore the efficacy of its treatment, depends not only on the occurrence of one ischaemic event, but rather on cumulative events experienced by patients. Accordingly, we conducted a post-hoc analysis of the MIRACL trial to examine the effect of atorvastatin on first as well as recurrent (i.e. total) hard cardiovascular events after ACS (death, myocardial infarction, stroke, and resuscitated cardiac arrest). Methods and Results In the 3086 patients who comprised the MIRACL trial, atorvastatin 80 mg did not reduce time to first hard event compared with placebo (hazard ratio 0.89, 95% confidence interval 0.72-1.10, P = 0.27). However, atorvastatin significantly reduced total hard events (hazard ratio 0.80, 95% confidence interval 0.66-0.97, P = 0.03). To prevent one hard event during the 16 weeks following ACS, only 11 patient-years of treatment with atorvastatin were required. Conclusion Early, intensive treatment with atorvastatin is an efficient intervention to reduce hard cardiovascular events after ACS.

Overview

Integrity signals

Registry

Crossref · 10.1177/2047487317708677

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 7 references

Cited by

See all 46

Metadata

Authors
Schwartz, G. G., Fayyad, R., Szarek, M., DeMicco, D., & Olsson, A. G.
Affiliations
  • VA Medical Center and University of Colorado, USA
  • Pfizer (United States) (US)
  • SUNY Downstate Health Sciences University (US)
  • Linköping University (SE)
Corresponding author
Schwartz, Gregory G
Venue
European Journal of Preventive Cardiology
Published
2017-05-15
Volume
24
Issue
12
Pages
1294-1296
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W2615974387
Cited by
44
References
7
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 15 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 2
FWCI
4.20
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • European Journal of Preventive Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
acute coronary syndrome, atorvastatin, statin therapy, recurrent cardiovascular events, post hoc analysis, myocardial infarction, stroke, resuscitated cardiac arrest
MeSH terms
Cause of Death, Dose-Response Relationship, Drug, Humans, Morbidity, Global Health, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Acute Coronary Syndrome, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early, intensive statin treatment reduces ‘hard’ cardiovascular outcomes after acute coronary syndrome. https://app.cochat.ai/papers/10.1177/2047487317708677
The paper
Schwartz, G. G., Fayyad, R., Szarek, M., DeMicco, D., & Olsson, A. G. (2017). Early, intensive statin treatment reduces ‘hard’ cardiovascular outcomes after acute coronary syndrome. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487317708677

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.